Do you want to read an article? Please log in or register.
Treatment Outcomes of Ranibizumab versus Aflibercept for Neovascular Age-Related Macular Degeneration: Data from the Fight Retinal Blindness! Registry
Macular Diseases
Related content
Macular Diseases
Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naive neovascular age-related macular degeneration: real world data from the Fight Retinal Blindness registry
Graefes Arch Clin Exp Ophthalmol
Figueras-Roca M, Parrado-Carrillo A, Nguyen V, Casaroli-Marano RP, Moll-Udina A, Gillies MC, Barthelmes D, Zarranz-Ventura J
doi: 10.1007/s00417-020-05016-9
Macular Diseases
SMOKING STATUS AND TREATMENT OUTCOMES OF VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Retina.
Vittorio AF, Nguyen V, Barthelmes D, Arnold JJ, Cheung CMG, Murray N, Gillies MC, Fight Retinal Blindness! Study Group.
doi: 10.1097/IAE.0000000000002679.
COMMENTED
Macular DiseasesRetinal Diseases
INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Retina.
Vazquez-Alfageme C, Nicholson L, Hamilton RD, Patel PJ
doi: 10.1097/IAE.
Macular DiseasesRetinal Diseases
Neovascular age-related macular degeneration: A review of findings from the real-world Fight Retinal Blindness! registry
Clin Exp Ophthalmol
Nguyen V, Barthelmes D, Gillies MC
doi: 10.1111/ceo.13949
RECOMMENDED
Macular Diseases
FIVE-YEAR INCIDENCE AND VISUAL ACUITY OUTCOMES FOR INTRAVITREAL THERAPY IN BILATERAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Fight Retinal Blindness! Project
★ 2
Recommended by
PD Dr Moreno Menghini, Faculty Member
doi: 10.1097/IAE.0000000000002798.
Macular DiseasesRetinal Diseases
Six-year outcomes in neovascular age-related macular degeneration with ranibizumab
Int J Ophthalmol.
Jacob J, Brié H, Leys A, Levecq L, Mergaerts F, Denhaerynck K, Vancayzeele S, Van Craeyveld E, Abraham I, MacDonald K
doi: 10.18240/ijo.2017.01.14.
Macular DiseasesRetinal Diseases
One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration
Br J Ophthalmol.
Braimah IZ, Agarwal K, Mansour A, Chhablani J; Ziv-aflibercept Study Group
doi: 10.1136/bjophthalmol-
Macular Diseases
The effect of ranibizumab and aflibercept treatment on the prevalence of outer retinal tubulation and its influence on retreatment in neovascular age-related macular degeneration
BMC Ophthalmol.
Kovacs A, Kiss T, Rarosi F, Somfai GM, Facsko A, Degi R
doi: 10.1186/s12886-018-0960-6.
Macular Diseases
Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study
Br J Ophthalmol.
Gale RP, Pearce I, Eter N, Ghanchi F, Holz FG, Schmitz-Valckenberg S, Balaskas K, Burton BJL, Downes SM, Eleftheriadis H, George S, Gilmour D, Hamilton R, Lotery AJ, Patel N, Prakash P, Santiago C, Thomas S, Varma D, Walters G, Williams M, Wolf A, Zakri RH, Igwe F, Ayan F
doi: 10.1136/bjophthalmol-2019-314251.